Clinical Plenary #2
Nov
13
2023
Auditorium
-
Hynes Convention Center
9:00
- 10:00 AM EST
Description
Abstracts
- RECOMPENSATION OF CHRONIC HEPATITIS C-RELATED DECOMPENSATED CIRRHOSIS FOLLOWING DIRECT-ACTING ANTIVIRAL THERAPY: REAL-WORLD DATA FROM THE PUNJAB HCV ELIMINATION MODEL.
- ANALYZING NEW ONSET HEPATIC DECOMPENSATION AND LONG TERM ABSTINENCE/CRAVING IN PATIENTS WITH ALCOHOL ASSOCIATED LIVER DISEASES(AALD): A DOUBLE BLIND RANDOMIZED CONTROL TRIAL (RCT) FOR EFFECTIVENESS OF SELF ADMINISTERED 12 WEEKS 50 MG ORAL NALTREXONE VERSUS PLACEBO; ALONG WITH STANDARD COUNSELLING
- MOLECULAR SIGNATURES TO PREDICT RISK OF HEPATOCELLULAR CARCINOMA POST HEPATITIS C CURE
- POSITIVE RESULTS FROM THE ALPINE 4 STUDY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2b TRIAL EVALUATING MULTIPLE DOSES OF THE FGF19 ANALOGUE ALDAFERMIN IN PATIENTS WITH COMPENSATED CIRRHOSIS DUE TO NONALCOHOLIC STEATOHEPATITIS